Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

ClinicalTrials.gov ID: NCT05595460

Public ClinicalTrials.gov record NCT05595460. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1b Single Arm, Open-label Trial of RYZ101 in Combination With Carboplatin + Etoposide + Atezolizumab in Subjects With Somatostatin Receptor Expressing (SSTR+) Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.

Study identification

NCT ID: NCT05595460
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: RayzeBio, Inc.; Industry
Enrollment: 21 participants

Conditions and interventions

Conditions

SCLC,Extensive Stage

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 10, 2022 (Actual)
Primary completion: Jul 2027 (Estimated)
Completion: Jul 2027 (Estimated)
Last update posted: Apr 13, 2026

2022 – 2027

United States locations

U.S. sites: 12
U.S. states: 9
U.S. cities: 12

Facility	City	State	ZIP	Site status
Research Facility	Los Angeles	California	90024	—
Research Facility	San Francisco	California	94158	—
Research Facility	Jacksonville	Florida	32224	—
Research Facility	Miami	Florida	33136	—
Research Facility	Orlando	Florida	32806	—
Research Facility	Iowa City	Iowa	52242	—
Reserach Facility	Lexington	Kentucky	40536	—
Research Facility	Grand Rapids	Michigan	49503	—
Research Facility	Rochester	Minnesota	55905	—
Research Facility	St Louis	Missouri	63130	—
Research Facility	Omaha	Nebraska	68130	—
Research Facility	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05595460, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 13, 2026 · Synced Oct 17, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05595460 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →